| Related Articles |
The diagnostic value of serum copeptin levels in an acute pulmonary embolism.
Cardiol J. 2015 Dec 29;
Authors: Kalkan AK, Ozturk D, Erturk M, Kalkan ME, Cakmak HA, Oner E, Uzun F, Tasbulak O, Yakisan T, Celik A
Abstract
BACKGROUND: Acute pulmonary embolism (APE) is a common disease which is associated with high mortality and morbidity. Circulating level of copeptin, which was demonstrated to be elevated in heart failure, acute myocardial infarction and pulmonary arterial hypertension, was reported to be an independent predictor of poor outcome in recent studies. The aim of the present study was to investigate the clinical utility of copeptin in the diagnosis of APE.
METHODS: A total of 90 consecutive patients, who admitted to emergency service for acute chest pain and/or dyspnea and underwent pulmonary computerized tomography (CT) angiography due to suspicion of APE, were included in this prospective study. The patients diagnosed with APE were defined as APE (+) group and the remaining individuals with normal pulmonary CT angiography result defined as APE (-) group.
RESULTS: Copeptin levels (7.76 ± 4.4 vs. 3.81 ± 1.34 ng/dl; p < 0.001) were higher in the APE (+) group as compared to the APE (-) group. Copeptin was significantly positively correlated with brain-natriuretic peptide (r=0.434, p<0.001), D-dimer (r=0.315, p=0.003) and troponin I (r=0.300, p=0.004) and inversely correlated with arterial oxygen saturations (r = - 0.533 ; p <0001). When the correlation of copeptin with right ventricular dysfunction parameters was investigated, it was significantly inversely correlated with the tricuspid annular plane systolic excursion (TAPSE) (r = -0.521, p < 0.001) and positively correlated with right to left ventricle ratio (RV/LV) ratio (r = 0.329, p = 0.024). Copeptin (OR:1.836, 95% CI:1.171-2.878, p = 0.008) was found as a significant independent predictor of APE in a multivariate analysis, after adjusting for other risk parameters.
CONCLUSIONS: Copeptin is a promising new biomarker, which may be used to support the need for further investigations and to improve the diagnosis of patients with APE.
PMID: 26711465 [PubMed - as supplied by publisher]